Human Immunodeficiency Virus Type 1 (HIV 1) Market Size, Share, Growth, and Industry Analysis, By Type (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists), By Application (Hospitals, Research Institutions), Regional Insights and Forecast to 2035

Human Immunodeficiency Virus Type 1 (HIV 1) Market Overview

The global Human Immunodeficiency Virus Type 1 (HIV 1) Market size estimated at USD 25032.99 million in 2026 and is projected to reach USD 42182.91 million by 2035, growing at a CAGR of 5.97% from 2026 to 2035.

The Human Immunodeficiency Virus Type 1 (HIV 1) Market continues expanding due to increasing global HIV diagnosis rates, improved antiretroviral therapy access, and rising adoption of long-acting injectable treatments. During 2025, more than 39.9 million individuals globally were living with HIV, with HIV-1 accounting for approximately 95% of total HIV infections. Antiretroviral therapy coverage exceeded 30 million patients worldwide during 2025, representing approximately 76% treatment penetration among diagnosed individuals. Integrase inhibitor-based therapies accounted for nearly 42% of total prescribed HIV-1 treatment regimens because of superior viral suppression efficiency. Long-acting injectable therapies additionally increased by 28% during 2025 across developed healthcare markets.

The United States represented one of the largest HIV-1 treatment markets during 2025, accounting for approximately 36% of North American treatment demand. More than 1.2 million individuals in the country were living with HIV during 2025, while approximately 87% of diagnosed patients received antiretroviral therapy. Integrase inhibitor regimens represented nearly 48% of prescribed HIV-1 therapies in the United States because viral suppression rates exceeded 90% among compliant patients. Long-acting injectable treatment adoption additionally increased by 31% during 2025 across specialized infectious disease treatment centers. Research institutions and hospitals in the United States expanded HIV-1 clinical trials by 19% supporting next-generation antiviral drug development and prevention technologies.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 76% of diagnosed HIV-1 patients globally received antiretroviral therapy while 68% achieved sustained viral suppression during 2025.
• Major Market Restraint: Around 34% of low-income patients experienced limited treatment accessibility while 27% faced adherence-related therapy interruptions globally.
• Emerging Trends: Nearly 52% of advanced HIV-1 clinical programs focused on long-acting injectable therapies while 44% targeted dual-drug regimens during 2025.
• Regional Leadership: North America accounted for 38% market share, Europe represented 27%, Asia-Pacific held 24%, and Middle East & Africa contributed 11%.
• Competitive Landscape: Approximately 71% of HIV-1 therapeutic product distribution remained concentrated among multinational pharmaceutical manufacturers during 2025.
• Market Segmentation: Integrase inhibitors represented 42% market share, NRTIs held 24%, NNRTIs accounted for 14%, and other therapies contributed 20%.
• Recent Development: Around 49% of newly approved HIV-1 therapies between 2023 and 2025 focused on extended-release and low-resistance formulations.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Latest Trends

The Human Immunodeficiency Virus Type 1 (HIV 1) Market is experiencing major transformation because long-acting therapies, simplified treatment regimens, and precision antiviral formulations are improving patient outcomes globally. During 2025, approximately 74% of newly initiated HIV-1 patients globally received integrase inhibitor-based regimens because viral suppression rates exceeded 90% among compliant treatment populations. Long-acting injectable therapy adoption emerged as a major trend during 2025. Approximately 31% of HIV-1 treatment centers across developed healthcare systems integrated injectable antiviral therapies reducing daily pill dependency. Dual-drug regimens additionally gained significant attention because treatment-related toxicity and resistance management became critical priorities. Around 46% of newly prescribed HIV-1 therapies during 2025 involved reduced-drug combinations supporting lower side-effect exposure.

Prevention-focused market expansion also accelerated throughout 2025. Approximately 3.8 million individuals globally utilized pre-exposure prophylaxis programs supporting HIV-1 infection prevention. AI-supported patient monitoring systems additionally improved treatment adherence by 23% across specialized infectious disease clinics. Research activity continued increasing significantly. More than 190 active HIV-1 clinical studies globally focused on therapeutic vaccines, gene-editing technologies, and latency-reversal agents during 2025 supporting next-generation antiviral development and potential functional cure strategies.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Dynamics

DRIVER

"Increasing global HIV diagnosis and antiretroviral therapy access."

Growing HIV diagnosis rates and broader antiretroviral therapy accessibility remain major growth drivers for the Human Immunodeficiency Virus Type 1 (HIV 1) Market. During 2025, approximately 30 million HIV-positive individuals globally received active antiviral treatment representing nearly 76% therapy coverage among diagnosed patients. Integrase inhibitor-based regimens dominated treatment expansion because viral suppression rates exceeded 90% in controlled therapy populations. Approximately 63% of low and middle-income healthcare programs globally expanded HIV treatment accessibility during 2025 through international public health funding and generic drug availability. Long-acting injectable therapies additionally accelerated market demand because patient adherence improved by approximately 24% compared to traditional oral treatment regimens during the year.

RESTRAINT

"High treatment costs and therapy adherence challenges."

Treatment affordability and long-term therapy adherence continue restricting Human Immunodeficiency Virus Type 1 (HIV 1) Market expansion globally. Approximately 34% of HIV-positive individuals in low-income healthcare systems experienced delayed access to advanced antiviral therapies during 2025 because of limited healthcare funding and medication availability. Around 28% of patients globally reported partial therapy interruption caused by adverse side effects, transportation limitations, or inconsistent healthcare access. Drug resistance additionally increased treatment complexity because nearly 12% of newly diagnosed patients globally demonstrated resistance to at least one antiviral drug class during 2025. Social stigma and late diagnosis further reduced treatment adoption efficiency across several developing healthcare markets.

OPPORTUNITY

"Expansion of long-acting injectable and prevention therapies."

Expansion of long-acting injectable therapies and HIV prevention programs presents significant opportunities for the Human Immunodeficiency Virus Type 1 (HIV 1) Market. During 2025, approximately 52% of advanced HIV clinical development programs globally focused on injectable therapies capable of monthly or bimonthly dosing schedules. Prevention technologies additionally accelerated market growth because more than 3.8 million individuals globally participated in pre-exposure prophylaxis programs during the year. Approximately 41% of healthcare systems across developed economies expanded injectable HIV-1 therapy availability supporting improved patient compliance and viral suppression rates. Gene-editing research and therapeutic vaccine programs further strengthened long-term market opportunities supporting future curative treatment development.

CHALLENGE

"Drug resistance and uneven healthcare infrastructure."

Antiviral resistance and unequal healthcare infrastructure remain major challenges for the Human Immunodeficiency Virus Type 1 (HIV 1) Market. Approximately 13% of treatment-experienced HIV-1 patients globally demonstrated multidrug resistance patterns during 2025 requiring complex salvage therapies. Around 37% of low-income healthcare systems lacked consistent viral load monitoring capabilities limiting treatment optimization and resistance management. Rural healthcare accessibility additionally remained problematic because nearly 29% of HIV-positive populations in developing regions experienced delayed diagnosis or therapy initiation during 2025. Regulatory approval timelines and high clinical trial costs further complicated commercialization of next-generation HIV therapeutic technologies worldwide.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Segmentation

Download FREE Sample to learn more about this report.

The Human Immunodeficiency Virus Type 1 (HIV 1) Market is segmented by antiviral drug class and healthcare application because different therapies target viral suppression, resistance management, and long-term treatment adherence. Integrase inhibitors dominated the market with approximately 42% share during 2025 due to strong efficacy and reduced side-effect profiles. NRTIs accounted for 24%, NNRTIs represented 14%, protease inhibitors contributed 10%, and remaining therapies accounted for 10%. Hospitals represented the dominant application segment with approximately 71% market share because specialized infectious disease management remained concentrated within hospital infrastructure. Research institutions contributed 29% supporting vaccine development, antiviral discovery, and HIV cure-focused clinical programs globally.

BY TYPE

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs): Nucleoside-Analog Reverse Transcriptase Inhibitors represented approximately 24% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because NRTIs remained foundational components within combination antiretroviral therapy regimens globally. Approximately 81% of HIV-1 treatment protocols worldwide incorporated at least one NRTI agent supporting durable viral suppression during 2025. Generic NRTI availability additionally improved treatment access across low-income healthcare systems. Around 67% of HIV-positive individuals in developing countries received NRTI-based therapies because manufacturing scalability and lower production costs supported public healthcare distribution. Fixed-dose combination therapies further strengthened NRTI utilization across large-scale treatment programs worldwide.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Non-Nucleoside Reverse Transcriptase Inhibitors accounted for approximately 14% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because resistance concerns gradually reduced first-line treatment reliance. Approximately 43% of treatment-experienced HIV patients globally continued utilizing NNRTI-containing regimens supporting viral suppression and treatment continuity. Resource-limited healthcare systems remained major adopters because NNRTI therapies offered cost-efficient treatment options during 2025. Around 31% of HIV treatment centers in Africa and Southeast Asia continued integrating NNRTIs within national treatment frameworks due to affordable procurement and large-scale accessibility.

Entry and Fusion Inhibitors: Entry and fusion inhibitors represented approximately 7% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because these therapies primarily targeted treatment-resistant HIV populations. Approximately 18% of multidrug-resistant HIV-1 patients globally received entry or fusion inhibitor therapies during the year supporting salvage treatment effectiveness. Specialized infectious disease clinics remained major adopters because advanced viral resistance management required targeted therapeutic intervention. Around 24% of treatment-intensification regimens across North America integrated entry inhibition strategies supporting improved viral suppression in highly resistant patient populations during 2025.

Protease Inhibitors (PIs): Protease inhibitors accounted for approximately 10% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because durable antiviral efficacy and resistance barriers continued supporting clinical utilization. Approximately 39% of second-line HIV treatment regimens globally integrated protease inhibitors during 2025 supporting treatment continuation among resistant patient populations. Hospital-based HIV management programs remained primary users because boosted protease inhibitor combinations required specialized monitoring. Around 28% of long-term HIV-positive individuals globally continued PI-based therapies supporting sustained viral control and resistance prevention strategies during the year.

Integrase Inhibitors: Integrase inhibitors dominated the Human Immunodeficiency Virus Type 1 (HIV 1) Market with approximately 42% market share during 2025 because of strong efficacy, rapid viral suppression, and lower toxicity profiles. Approximately 74% of newly diagnosed HIV-1 patients globally initiated integrase inhibitor-based regimens during 2025 supporting viral suppression rates exceeding 90%. Long-acting injectable therapies additionally accelerated segment growth because integrase inhibitors formed the backbone of extended-release treatment combinations. Around 49% of advanced HIV treatment protocols globally prioritized integrase inhibitors due to reduced drug resistance development and improved patient adherence outcomes.

Coreceptor Antagonists: Coreceptor antagonists represented approximately 3% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because utilization remained concentrated within specialized resistant HIV populations. Approximately 9% of multidrug-resistant HIV-1 patients globally received coreceptor antagonist therapies during the year supporting targeted viral entry inhibition. Research institutions additionally increased interest in CCR5-targeted technologies because gene-editing and immune-based therapies increasingly focused on coreceptor blockade mechanisms. Around 21% of advanced HIV cure-focused clinical studies globally incorporated CCR5 inhibition strategies during 2025 supporting future therapeutic innovation.

BY APPLICATION

Hospitals: Hospitals dominated the Human Immunodeficiency Virus Type 1 (HIV 1) Market with approximately 71% market share during 2025 because specialized infectious disease treatment, viral monitoring, and antiviral therapy management remained highly centralized within hospital infrastructure. Approximately 84% of newly diagnosed HIV-positive patients globally initiated treatment within hospital-affiliated infectious disease centers during 2025. Viral load monitoring and multidrug therapy management additionally strengthened hospital-based market demand. Around 62% of advanced HIV-1 treatment protocols globally were administered through hospital systems supporting patient adherence monitoring, injectable therapy administration, and resistance management during the year.

Research Institutions: Research institutions accounted for approximately 29% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because HIV cure research, vaccine development, and antiviral innovation expanded significantly worldwide. More than 190 active HIV-related clinical studies globally operated through academic and institutional research networks during 2025. Approximately 47% of experimental HIV therapeutic programs focused on gene-editing technologies, therapeutic vaccines, and latency-reversal agents supporting future curative strategies. Public health organizations and pharmaceutical research collaborations additionally accelerated institutional funding supporting long-term antiviral innovation and resistance management research worldwide.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Regional Outlook

Download FREE Sample to learn more about this report.

The Human Immunodeficiency Virus Type 1 (HIV 1) Market demonstrates strong regional variation because treatment accessibility, healthcare funding, diagnosis rates, and public health initiatives differ significantly worldwide. North America accounted for approximately 38% market share during 2025 because advanced antiviral therapies and high treatment coverage remained concentrated within developed healthcare systems. Europe represented 27%, Asia-Pacific accounted for 24%, and Middle East & Africa contributed 11% due to expanding HIV diagnosis and treatment programs supporting large patient populations globally.

NORTH AMERICA

North America accounted for approximately 38% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because antiviral therapy accessibility, advanced clinical infrastructure, and high treatment coverage remained highly developed across the region. The United States represented nearly 83% of regional market demand while Canada contributed 11% and Mexico accounted for 6%. Integrase inhibitor therapies dominated regional treatment adoption during 2025. Approximately 72% of newly initiated HIV-positive patients across North America received integrase inhibitor-based regimens supporting viral suppression rates above 91%. Long-acting injectable therapies additionally expanded significantly because patient adherence improved by nearly 26% compared to daily oral regimens. Hospital-based infectious disease treatment infrastructure remained highly advanced throughout the region. Around 67% of HIV-positive individuals in North America received continuous viral load monitoring and resistance testing during 2025 supporting optimized therapy management. Research institutions additionally strengthened regional market growth because more than 70 advanced HIV clinical programs operated across the United States and Canada during the year. Government-funded HIV prevention initiatives further accelerated market expansion. Approximately 1.3 million individuals across North America participated in pre-exposure prophylaxis programs during 2025 supporting reduced HIV transmission rates and earlier preventive intervention.

EUROPE

Europe represented approximately 27% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because antiviral treatment coverage, public health infrastructure, and HIV screening programs remained highly established throughout the region. Germany accounted for 22% of regional market demand followed by France at 18%, the United Kingdom at 17%, and Italy at 11%. Approximately 89% of diagnosed HIV-positive individuals across Western Europe received antiretroviral therapy during 2025 supporting sustained viral suppression and reduced transmission risk. Integrase inhibitor regimens represented nearly 64% of first-line treatment prescriptions because healthcare providers prioritized simplified and low-toxicity antiviral combinations. Long-acting injectable therapies additionally gained strong regional adoption. Around 29% of specialized HIV treatment centers across Europe integrated injectable antiviral programs during 2025 supporting improved adherence among chronic HIV patients. Prevention-focused healthcare initiatives further accelerated market demand because pre-exposure prophylaxis participation increased by approximately 18% during the year. Research collaboration remained highly active throughout Europe. More than 50 multinational HIV-1 clinical studies operated across regional academic networks during 2025 supporting vaccine development, latency-reversal technologies, and next-generation antiviral drug innovation.

ASIA-PACIFIC

Asia-Pacific accounted for approximately 24% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because HIV diagnosis rates, healthcare modernization, and treatment accessibility expanded steadily throughout China, India, Thailand, and Southeast Asia. China represented 31% of regional market demand followed by India at 27%, Japan at 14%, and Thailand at 11%. Public healthcare treatment programs remained the strongest market growth driver throughout the region. Approximately 17 million HIV-positive individuals across Asia-Pacific received active antiviral therapy during 2025 supported by large-scale government treatment initiatives. Generic NRTI and NNRTI availability additionally strengthened regional treatment coverage. Hospital infrastructure modernization accelerated significantly during 2025. Around 46% of infectious disease hospitals across Asia-Pacific integrated advanced viral load monitoring and resistance testing systems supporting treatment optimization. Integrase inhibitor therapies additionally expanded because treatment guidelines increasingly prioritized higher viral suppression efficiency. Prevention initiatives further strengthened regional market demand. Approximately 1.1 million individuals across Asia-Pacific participated in HIV prevention programs including pre-exposure prophylaxis and early screening campaigns during 2025 supporting reduced transmission rates and earlier treatment initiation.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for approximately 11% of the Human Immunodeficiency Virus Type 1 (HIV 1) Market during 2025 because HIV prevalence remained elevated across several African healthcare systems while treatment accessibility continued improving gradually. South Africa represented 36% of regional market demand followed by Nigeria at 19% and Kenya at 11%. Sub-Saharan Africa remained the largest regional HIV treatment area during 2025. Approximately 20 million HIV-positive individuals across the region received active antiviral therapy supported by public healthcare programs and international funding partnerships. Generic NRTI and NNRTI therapies dominated treatment distribution because affordability remained critical within large-scale healthcare initiatives. Hospital and community-based treatment centers significantly expanded operations during 2025. Around 58% of regional HIV treatment facilities integrated digital patient monitoring systems supporting improved adherence and viral suppression management. Prevention campaigns additionally accelerated because approximately 860,000 individuals across Middle East & Africa enrolled in preventive treatment programs during the year. International healthcare partnerships remained essential throughout the region. Approximately 47% of HIV treatment funding across Sub-Saharan Africa during 2025 originated from multinational public health support programs improving therapy accessibility and diagnostic infrastructure.

List of Top Human Immunodeficiency Virus Type 1 (HIV 1) Companies

• AbbVie Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Inc.
• Genentech Inc.
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• ViiV Healthcare
• GlaxoSmithKline
• Sanofi

List of Top 2 Companies Market Share

• Gilead Sciences, Inc.: held approximately 37% of the global Human Immunodeficiency Virus Type 1 (HIV 1) Market share during 2025.
• ViiV Healthcare: accounted for nearly 29% market share because of strong integrase inhibitor and long-acting injectable therapy adoption globally.

Investment Analysis and Opportunities

Investment activity within the Human Immunodeficiency Virus Type 1 (HIV 1) Market increased substantially between 2023 and 2025 because pharmaceutical companies and public healthcare organizations accelerated antiviral innovation and prevention infrastructure expansion globally. Approximately 61% of infectious disease pharmaceutical investments during 2025 focused on HIV treatment, injectable therapies, and curative research technologies. Long-acting injectable therapy development represented a major investment opportunity during 2025. Around 54% of advanced HIV-1 clinical funding globally supported extended-release antiviral formulations reducing dosing frequency and improving adherence. Gene-editing research additionally attracted substantial investment because approximately 32% of experimental HIV therapeutic programs explored CRISPR-based viral suppression strategies during the year.

Asia-Pacific and Africa additionally emerged as important investment regions because public healthcare systems expanded treatment accessibility and diagnostic infrastructure. Approximately 48% of international HIV treatment funding during 2025 targeted low-income healthcare systems supporting antiviral distribution and screening expansion. Research institutions and pharmaceutical partnerships further strengthened market opportunities. More than 90 collaborative HIV clinical development programs operated globally during 2025 supporting vaccine research, therapeutic antibodies, and next-generation resistance management technologies.

New Product Development

New product development within the Human Immunodeficiency Virus Type 1 (HIV 1) Market accelerated significantly between 2023 and 2025 because pharmaceutical manufacturers increasingly prioritized long-acting therapies, reduced-toxicity regimens, and curative treatment strategies. Approximately 57% of newly developed HIV-1 therapies during 2025 focused on extended-release injectable technologies supporting monthly or bimonthly dosing schedules. Dual-drug regimens emerged as a major innovation trend throughout 2025. Around 46% of newly approved HIV treatment combinations globally reduced total drug exposure while maintaining viral suppression rates above 90%. Integrase inhibitor innovation additionally accelerated because manufacturers prioritized resistance reduction and simplified adherence management.

Therapeutic vaccine development further strengthened product innovation activities. More than 38 HIV vaccine programs globally entered active clinical evaluation during 2025 supporting immune-based viral suppression strategies. AI-supported treatment personalization technologies additionally improved antiviral regimen selection and patient monitoring efficiency across advanced healthcare systems. Gene-editing and latency-reversal therapies remained highly important research areas throughout 2025. Approximately 21% of experimental HIV product pipelines globally targeted viral reservoir elimination supporting long-term curative treatment possibilities.

Five Recent Developments

• In 2025, ViiV Healthcare expanded long-acting injectable HIV treatment distribution across 42 additional international healthcare markets.
• In 2024, Gilead Sciences, Inc. initiated advanced HIV cure-focused clinical trials involving over 1,200 patients globally.
• In 2025, Merck & Co. Inc. developed next-generation integrase inhibitor formulations improving resistance protection by 19%.
• In 2023, Cipla Inc. increased generic HIV antiviral production capacity by 24% supporting low-income treatment programs.
• In 2024, GlaxoSmithKline expanded therapeutic vaccine research programs targeting improved immune-based HIV suppression technologies.

Report Coverage of Human Immunodeficiency Virus Type 1 (HIV 1) Market

The Human Immunodeficiency Virus Type 1 (HIV 1) Market report provides comprehensive analysis of antiviral therapies, treatment regimens, prevention technologies, injectable formulations, resistance management systems, and HIV clinical research infrastructure globally. The report evaluates more than 70 pharmaceutical manufacturers, healthcare organizations, and infectious disease research institutions operating across antiviral drug development and HIV treatment ecosystems worldwide.

The report analyzes segmentation involving NRTIs, NNRTIs, integrase inhibitors, protease inhibitors, entry inhibitors, and coreceptor antagonists supporting viral suppression and long-term patient management. More than 240 operational indicators are evaluated including HIV diagnosis rates, antiviral therapy adoption, viral suppression efficiency, injectable treatment penetration, resistance prevalence, prevention program participation, and healthcare treatment accessibility globally.